Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer
Breast cancer is the second leading cause of cancer death among women. Human epidermal receptor 2 (HER2) positive breast cancer (HER2+ BC) is the most aggressive subtype of breast cancer, with poor prognosis and a high rate of recurrence. About one third of breast cancer is HER2+ BC with significant...
Main Authors: | Quanxia Lv, Ziyuan Meng, Yuanyuan Yu, Feng Jiang, Daogang Guan, Chao Liang, Junwei Zhou, Aiping Lu, Ge Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2016-12-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | http://www.mdpi.com/1422-0067/17/12/2095 |
Similar Items
-
Human epidermal growth factor receptor targeted inhibitors for the treatment of ovarian cancer
by: Maria Bonello, et al.
Published: (2018-12-01) -
Antibody–Drug Conjugates for Cancer Therapy
by: Umbreen Hafeez, et al.
Published: (2020-10-01) -
Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy
by: Hao Chen, et al.
Published: (2017-08-01) -
Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy
by: Natalie S. Grover, et al.
Published: (2015-09-01) -
Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions
by: Emanuela Ferraro, et al.
Published: (2021-08-01)